Marmosets as a preclinical model for testing “off-label” use of doxycycline to turn on Flt3L expression from high-capacity adenovirus vectors

Documenti analoghi

• Effectiveness and Preclinical Safety Profile of Doxycycline to Be Used “Off-Label” to Induce Therapeutic Transgene Expression in a Phase I Clinical Trial for Glioma
  di: VanderVeen, Nathan, et al.
  Pubblicazione: (2013)
• Preclinical Efficacy and Safety Profile of Allometrically Scaled Doses of Doxycycline Used to Turn “On” Therapeutic Transgene Expression from High-Capacity Adenoviral Vectors in a Glioma Model
  di: VanderVeen, Nathan, et al.
  Pubblicazione: (2016)
• Preclinical Characterization of Signal Transducer and Activator of Transcription 3 Small Molecule Inhibitors for Primary and Metastatic Brain Cancer Therapy
  di: Assi, Hikmat H., et al.
  Pubblicazione: (2014)
• Safety Profile, Efficacy, and Biodistribution of a Bicistronic High-Capacity Adenovirus Vector Encoding a Combined Immunostimulation and Cytotoxic Gene Therapy as a Prelude to a Phase I Clinical Trial for Glioblastoma
  di: Puntel, Mariana, et al.
  Pubblicazione: (2013)
• Preclinical trial on the use of doxycycline for the treatment of adenocarcinoma of the duodenum
  di: Galván-Salazar, Hector R., et al.
  Pubblicazione: (2016)